Second quarter net losses for Atara Biotherapeutics outpaced analyst expectations, nearly doubling from the same period in 2017 to $50.9 million. Research and development costs rose 82.5 percent to $33.4 million, including new clinical trials, increased headcount and its recent expansion into a new R&D headquarters in Thousand Oaks. The company received positive results from…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
